Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Fondaparinux in SVT (SURPRISE)
NCT01499953Phase 3Completed
- Sponsor
- GWT-TUD
- Start
- Apr 2012
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in superficial vein thrombosis (SVT) (2 arms), sponsored by GWT-TUD. Primary endpoint: Rate of Objectively Confirmed VTE Complications at 45 days. Started Apr 2012; status: completed.
02
Drugs
rivaroxaban
03
Conditions
superficial vein thrombosis (SVT)
Beyond the preview
Go deeper on NCT01499953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01499953.